Fairvalue-Calculator Fairvalue-Calculator
EN DE

Zenicor Medical Systems AB (ZENI) Fair Value & Analysis

Healthcare · SE · Market cap 28.8M SEK

Pricekr 0.9600
Fair Valuekr 0.7700
Upside-19.8%
Quality95/100
Evidence: Medium Range kr 0.4600 – kr 1.09

Fair value as of: Jun 26, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Zenicor Medical Systems AB (ZENI) currently trades at kr 0.9600, while our model-based Fair Value estimate is kr 0.7700 — implying the stock looks roughly 19.8% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

About the company

Zenicor Medical Systems AB (publ), a medical technology company, provides products and solutions for the diagnosis of arrhythmia and stroke prevention. The company offers Zenicor One, a handheld ECG device for arrhythmia; Zenicor Flex, a device that provides ECG data and arrhythmia detection; and Zenicor View, a web-based system solution for all types of arrhythmia investigations. It also provides Zenicor Direct, a solution with interpretation services and services for device logistics. The company was incorporated in 2003 and is headquartered in Stockholm, Sweden.

Open the full interactive analysis →

Similar stocks

Frequently asked questions

Is Zenicor Medical Systems AB (ZENI) undervalued?
As of Jun 26, 2026, our model estimates a fair value of kr 0.7700 versus a price of kr 0.9600 — about −20% (overvalued). Model-based estimate, not financial advice.
What is the fair value of ZENI?
Our 21-model fair value for Zenicor Medical Systems AB is kr 0.7700 (as of Jun 26, 2026), built from audited fundamentals. The current price is kr 0.9600.
What is the quality score of ZENI?
Zenicor Medical Systems AB has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.